AlphAIAlphAI — Financial news for AI agents
fool.comAUG 212 min read$LTRN

Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript

Lantern Pharma (LTRN) reported Q2 2026 earnings with $7.1M net loss, $7.4M cash, and reduced R&D expenses. LP-300 showed 8.9-month median PFS in L858R patients. The company is advancing LP-184 trials and plans to raise capital for Open Medicine AI, a new AI subsidiary. Management highlighted potential partnerships and cost efficiencies.

Original reporting
fool.com
Published Aug 21, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 2:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$LTRNNeutralMed
01

Why it matters

The earnings release offers fresh data on cash, loss, and expense trends, informing short‑term trading decisions.

02

Market read

First‑report earnings for a micro‑cap biotech; may trigger modest price movement.

03

What to watch

Potential dilution from future financing and execution risk of AI platform commercialization.

Relevance 7/10Novelty 7/10Timing: after market open

Background

Lantern Pharma (LTRN) held its Q2 2026 earnings call, providing detailed financial and clinical updates.

Company-level read

Ticker impact

$LTRNNeutralMedium confidence
Context

Q2 2026 earnings release showing net loss of $7.1M, cash $7.4M and a 42% YoY drop in R&D expense.

Expected impact

Potential modest upside if investors focus on loss reduction and cash raise plans.

Evidence & confidence

Earnings are better than prior year but the company remains loss-making and will need additional capital.

Market effects

Sector

Highlights cost‑efficiency trends in AI‑driven biotech sector.

Regional

Limited to US micro‑cap biotech investors.

Global

Shows emerging AI‑drug discovery model, but impact confined to niche investors.

Counterpoint

What could challenge this read

Loss reduction may be overstated; cash burn could accelerate with upcoming capital raises.

Key entities

  • Company
    Lantern Pharma Inc.

    Biotech firm developing AI‑enabled drug discovery platforms.

  • Executive
    Panna Sharma

    President and CEO of Lantern Pharma.

Read at source← All news

Related articles

AUG 14
$LTRNMed

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Lantern Pharma Inc. (LTRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update Open Medicine AI Established as a Separate Company with Executed Commercial Licenses; Progression-Free Survival Benefit Deepens in EGFR Exon 21 L858R Lung Cancer with LP-300; EM

SEC EDGAR 8-K6 min
JUL 23
$LTRNMed

Lantern Pharma Receives U.S. Patent Allowance for LP

Lantern Pharma (NASDAQ: LTRN) said the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering patient selection and treatment for ovarian, primary liver, kidney and thyroid cancers using LP-184 (zirdafulven). The allowed claims relate to a three-gene biomarker signature (PTGR1, PTPN14, ASPH). Lantern cited a 45% disease control rate at or above the effective dose in Phase 1a and plans multiple Phase 1b/2 studies in 2026.

citybuzz.co3 min
OCT 3
$NKEHighAI 8/10

Analyst warns Nike's best quarter this year may be behind it

Nike (NKE) reported Q1 earnings beating estimates, but investors sold shares. Morgan Stanley warns this may be the best quarter of the year, citing inventory risks and weaker forecasts. Nike expects fiscal 2027 revenue to decline by a high single-digit percentage. Analysts cut price targets, with Morgan Stanley suggesting a 50% drop in EPS over the next three quarters.

finance.yahoo.com3 min
OCT 3
$CCLHighAI 8/10

Carnival (CCL) Reports Strong Q3 Earnings, Dividend Sustainabili

Carnival Corporation (CCL) reported Q3 earnings of $1.43 per share, beating estimates by $0.08. The company offers a 1.56% dividend yield with a 19% payout ratio, and its stock is fairly valued at $25.76. CCL has a GF Score of 76, reflecting strengths in profitability and valuation but weaknesses in financial strength. Institutional investors show mixed sentiment, with 9 gurus increasing positions and 4 trimming them, while insiders sold $13.5 million in shares over the past year.

gurufocus.com2 min
OCT 3
$MUMedAI 8/10

Micron Just Extended Its Forecast for the AI Build-Out to 2031. Its Stock Is Bound to Defy History.

Micron Technology updated its forecast, stating that customer demand for memory chips will extend to 2031, up from 2030. The company reported Q4 fiscal 2027 revenue of $54.2 billion, up from $41.5 billion last quarter and $11.3 billion year-over-year. Micron projects $61.5 billion in revenue for the next quarter, citing strong AI-driven demand and supply constraints.

fool.com2 min